Kalfa Nicolas, Philibert Pascal, Patte Catherine, Ecochard Aude, Duvillard Pierre, Baldet Pierre, Jaubert Francis, Fellous Marc, Sultan Charles
Unité d'Endocrinologie-Gynécologie Pédiatrique, Service de Pédiatrie 1, Hôpital Arnaud-de-Villeneuve, Montpellier, France.
Fertil Steril. 2007 Apr;87(4):896-901. doi: 10.1016/j.fertnstert.2006.11.016.
In the female gonad, FOXL2 is a key factor for proper differentiation of granulosa cells (GC) during folliculogenesis and its expression persists in the ovary after birth. The aim of this multicentric nationwide study was to determine whether FOXL2 expression varies during tumoral proliferation of GC cells in juvenile ovarian GC tumors (OGCT).
Nationwide retrospective study.
University Hospital of Montpellier, Department of Hormonology.
PATIENT(S): Between 1994 and 2004, 26 patients with juvenile OGCT were reported in the TGM95 database of the French Society for Childhood Cancer (SFCE) and from eight pediatric endocrinology centers. Immunohistochemistry was performed using an anti-FOXL2 antibody.
INTERVENTION(S): Immunohistochemistry studies of FOXL2 on OGCT slides.
MAIN OUTCOME MEASURE(S): Level of FOXL2 expression within the tumor, International Federation of Gynecology and Obstetrics classification, and tumor recurrences.
RESULT(S): FOXL2 expression was absent in the GC of 10 patients and was markedly reduced in the cells of 4 patients. Precocious pseudopuberty was more frequently the revealing symptom in the children with conserved FOXL2 expression. Patients with no or reduced expression of FOXL2 more frequently exhibited associated hemorrhagic ascites, higher mitotic activity in the tumor, and significantly more advanced oncologic staging. All patients requiring complementary treatment (n = 7; chemotherapy or complementary surgery) had reduced expression of FOXL2 in the tumor. All recurring OGCT exhibited a complete extinction of FOXL2 expression (n = 3).
CONCLUSION(S): These results show that FOXL2 is not expressed or is underexpressed in juvenile OGCT with an aggressive pattern of progression, and it thus may be a prognostic factor for these tumors.
在女性性腺中，FOXL2是卵泡发生过程中颗粒细胞（GC）正常分化的关键因素，其表达在出生后卵巢中持续存在。这项多中心全国性研究的目的是确定FOXL2表达在青少年卵巢颗粒细胞瘤（OGCT）中GC细胞肿瘤增殖过程中是否发生变化。
全国性回顾性研究。
蒙彼利埃大学医院内分泌科。
1994年至2004年间，法国儿童癌症协会（SFCE）的TGM95数据库以及八个儿科内分泌中心报告了26例青少年OGCT患者。使用抗FOXL2抗体进行免疫组织化学检测。
对OGCT切片进行FOXL2的免疫组织化学研究。
肿瘤内FOXL2表达水平、国际妇产科联盟分类以及肿瘤复发情况。
10例患者的GC中未检测到FOXL2表达，4例患者的细胞中FOXL2表达明显降低。性早熟假青春期在FOXL2表达保留的儿童中更常作为首发症状。FOXL2无表达或表达降低的患者更常出现相关的血性腹水、肿瘤有更高的有丝分裂活性以及明显更晚期的肿瘤分期。所有需要辅助治疗的患者（n = 7；化疗或辅助手术）肿瘤中FOXL2表达均降低。所有复发的OGCT均表现为FOXL2表达完全消失（n = 3）。
这些结果表明，FOXL2在具有侵袭性进展模式的青少年OGCT中不表达或表达不足，因此它可能是这些肿瘤的一个预后因素。
